



Europäisches Patentamt
European Patent Office
Office européen des brevets

10. 615. 252



(11) **EP 1 170 008 A1**

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
09.01.2002 Bulletin 2002/02

(21) Application number: 00114088.8

(22) Date of filing: 07.07.2000

(51) Int Cl.7: **A61K 31/19**, A61P 43/00,
A61P 35/00, A61P 35/02,
A61P 5/02, C12Q 1/66,
C12Q 1/34, G01N 33/68,
C12Q 1/68

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(71) Applicant: **CHEMOTHERAPEUTISCHES
FORSCHUNGSINSTITUT
GEORG-SPEYER-HAUS
D-60596 Frankfurt (DE)**

(72) Inventors:
• **Göttlicher, Martin Dr.
76297 Stutensee (DE)**

• **Heinzel, Thorsten Dr.
60529 Frankfurt am Main (DE)**
• **Groner, Bernd Prof. Dr.
60322 Frankfurt am Main (DE)**
• **Herrlich, Peter Prof. Dr.
76229 Karlsruhe (DE)**

(74) Representative: **Keller, Günter, Dr. et al
Lederer, Keller & Riederer Patentanwälte
Prinzregentenstrasse 16
80538 München (DE)**

(54) **Valproic acid and derivatives thereof as histone deacetylase inhibitors**

(57) The present invention relates to the use of valproic acid and derivatives thereof as an inhibitor of histone deacetylases. The invention also concerns the use of those compounds for the manufacture of a medicament for the treatment of diseases associated with histone hypoacetylation or in which a therapeutic effect can

be achieved by induction of increased histone acetylation, such as tumors or leukemias, myelodysplastic syndrome or thyroid resistance syndrome. Also provided are methods for screening compounds having histone deacetylase activity using valproic acid/derivative thereof, and methods for identifying genes induced by valproic acid/derivatives thereof.

EP 1 170 008 A1

Description

- [0001] The present invention relates to the use of the drug valproic acid and derivatives thereof as inhibitor of enzymes having histone deacetylase activity. The invention also relates to the use of those compounds for the manufacture of a medicament for the treatment of diseases which are associated with hypoacetylation of histones or in which induction of hyperacetylation has a beneficial effect.
- [0002] Local remodelling of chromatin is a key step in the transcriptional activation of genes. Dynamic changes in the nucleosomal packaging of DNA must occur to allow transcriptional proteins contact with the DNA template. One of the most important mechanisms contributing to chromatin remodelling is the posttranslational modification of histones by acetylation. Change in electrostatic attraction for DNA and steric hindrance introduced by the hydrophobic acetyl group leads to destabilisation of the interaction of histones with DNA. As a result, acetylation of histones disrupts nucleosomes and allows the DNA to become accessible to the transcriptional machinery. Removal of the acetyl groups allows the histones to bind more tightly to DNA and to adjacent nucleosomes and thus maintain a transcriptionally repressed chromatin structure. Acetylation is mediated by a series of enzymes with histone acetyltransferase (HAT) activity. Conversely, acetyl groups are removed by specific histone deacetylase (HDAC) enzymes. Disruption of these mechanisms gives rise to transcriptional misregulation and may lead to leukemic transformation.
- [0003] Nuclear hormone receptors are ligand-dependent transcription factors that control development and homeostasis through both positive and negative control of gene expression. Defects in these regulatory processes underlie the causes of many diseases and play an important role in the development of cancer.
- [0004] Several members of the nuclear receptor superfamily have been reported to interact with basal transcription factors, including TFIIB. However, numerous lines of evidence indicate that nuclear receptors must interact with additional factors to mediate both activation and repression of target genes. A number of cofactors that associate with the ligand binding domains of estrogen (ER), retinoic acid (RAR), thyroid hormone (T3R), retinoid X (RXR), and other nuclear receptors have recently been identified. Putative coactivator proteins include SRC-1 / NCoA-1, GRIP1 / TIF2 / NCoA-2, pCIP / ACTR / AIB1, CBP and a variety of other factors (reviewed in Xu et al., 1999, Curr Opin Genet Dev 9, 140-147). Interestingly, SRC proteins as well as CBP have been shown to harbor intrinsic histone acetyltransferase activity and to exist in a complex with the histone acetylase P/CAF.
- [0005] Many nuclear receptors, including T3R, RAR and PPAR, can interact with the corepressors N-CoR and SMRT in the absence of ligand and thereby inhibit transcription. Furthermore, N-CoR has also been reported to interact with antagonist-occupied progesterone and estrogen receptors. N-CoR and SMRT have been shown to exist in large protein complexes, which also contain mSin3 proteins and histone deacetylases. Thus, the ligand-induced switch of nuclear receptors from repression to activation reflects the exchange of corepressor and coactivator complexes with antagonistic enzymatic activities.
- [0006] The N-CoR corepressor complex not only mediates repression by nuclear receptors, but also interacts with additional transcription factors including Mad-1, BCL-6 and ETO. Many of these proteins play key roles in disorders of cell proliferation and differentiation. T3R for example was originally identified on the basis of its homology with the viral oncogene v-erbA, which in contrast to the wildtype receptor does not bind ligand and functions as a constitutive repressor of transcription. Furthermore, mutations in RARs have been associated with a number of human cancers, particularly acute promyelocytic leukemia (APL) and hepatocellular carcinoma. In APL patients RAR fusion proteins resulting from chromosomal translocations involve either the promyelocytic leukemia protein (PML) or the promyelocytic zinc finger protein (PLZF). Although both fusion proteins can interact with components of the corepressor complex, the addition of retinoic acid dismisses the corepressor complex from PML-RAR, whereas PLZF-RAR interacts constitutively. These findings provide an explanation why PML-RAR APL patients achieve complete remission following retinoic acid treatment whereas PLZF-RAR APL patients respond very poorly. The hypothesis that corepressor-mediated aberrant repression may be causal for pathogenesis in APL is supported by the finding that trichostatin A, which inhibits histone deacetylase (HDAC) function is capable of overcoming the differentiation block in cells containing the PLZF-RAR fusion protein. Furthermore, a PML-RAR patient who had experienced multiple relapses after treatment with retinoic acid has recently been treated with the HDAC inhibitor phenylbutyrate, resulting in complete remission of the leukemia (Warrell et al., 1998, J. Natl. Cancer Inst. 90, 1621-1625).
- [0007] Additional evidence that histone acetylation plays a role in cancer comes from studies on the AML1-ETO oncoprotein and on chromosomal rearrangements involving the MLL locus (Redner et al., 1999, Blood 94, 417-428).
- [0008] WO 99/37150 discloses a transcription therapy for cancer comprising administering a retinoid substance and an inhibitor of histone deacetylase.
- [0009] Several compounds are known to be HDAC inhibitors. Butyric acid, or butyrate, was the first HDAC inhibitor to be identified. In millimolar concentrations, butyrate is not specific for HDAC, it also inhibits phosphorylation and methylation of nucleoproteins as well as DNA methylation. Its analogue phenylbutyrate acts in a similar manner. More specific are trichostatin A (TSA) and trapoxin (TPX). TPX and TSA have emerged as potent inhibitors of histone deacetylases. TSA reversibly inhibits, whereas TPX irreversibly binds to and inactivates HDAC enzymes. Unlike butyrate,

nonspecific inhibition of other enzyme systems has not yet been reported for TSA or TPX. TSA and TPX, however, exhibit considerable toxicity and are therefore of limited therapeutic use.

[0010] It is an object of the present invention to provide substances which can be useful in the treatment of cancer.

[0011] It was surprisingly found that valproic acid (VPA; 2-n-propylpentanoic acid) is capable of inhibiting histone deacetylase.

[0012] Valproic acid is a known drug with multiple biological activities which depend on different molecular mechanisms of action.

- VPA is an antiepileptic drug.

- VPA is teratogenic. When used as antiepileptic drug during pregnancy VPA can induce birth defects (neural tube closure defects and other malformations) in a few percent of born children. In mice, VPA is teratogenic in the majority of mouse embryos when properly dosed.

- VPA activates a nuclear hormone receptor (PPAR δ). Several additional transcription factors are also derepressed but some factors are not significantly derepressed (glucocorticoid receptor, PPAR α).

- VPA is hepatotoxic, which may depend on poorly metabolized esters with coenzyme A.


[0013] The use of VPA derivatives allowed to determine that the different activities are mediated by different molecular mechanisms of action. Teratogenicity and antiepileptic activity follow different modes of action because compounds could be isolated which are either preferentially teratogenic or preferentially antiepileptic (Nau et al., 1991, Pharmacol. Toxicol. 69, 310-321). Activation of PPAR δ was found to be strictly correlated with teratogenicity (Lampen et al., 1999, Toxicol. Appl. Pharmacol. 160, 238-249) suggesting that, both, PPAR δ activation and teratogenicity require the same molecular activity of VPA. Also, differentiation of F9 cells strictly correlated with PPAR δ activation and teratogenicity as suggested by Lampen et al., 1999, and documented by the analysis of differentiation markers (Werling et al., manuscript in preparation). It is shown in the present application, that PPAR δ activation is caused by the HDAC inhibitory activity of VPA and its derivatives. Furthermore it is shown that the established HDAC inhibitor TSA activates PPAR δ and induces the same type of F9 cell differentiation as VPA. From these results we conclude that not only activation of PPAR δ but also induction of F9 cell differentiation and teratogenicity of VPA or VPA derivatives are most likely caused by HDAC inhibition.

[0014] Antiepileptic and sedating activities follow different structure activity relationships and thus obviously depend on a primary VPA activity distinct from HDAC inhibition.

[0015] The mechanism of hepatotoxicity is poorly understood and it is unknown whether it is associated with formation of the VPA-CoA ester. The use according to the invention, e.g. HDAC inhibition, however, appears not to require CoA ester formation.

[0016] US patent No. 5,672,746 discloses the use of VPA and derivatives thereof for the treatment of neurodegenerative and neuroproliferative disorders.

[0017] One aspect of the present invention is therefore the use of VPA and derivatives thereof as an inhibitor of an enzyme having histone deacetylase activity. Derivatives of VPA are compounds of formula I



wherein R¹ and R² independently are a linear or branched, saturated or unsaturated aliphatic C₁₋₂₅ hydrocarbon chain which chain optionally comprises one or several heteroatoms and which may be substituted, R³ is hydroxyl, halogen, alkoxy or an optionally alkylated amino group.

[0018] Different R¹ and R² residues give rise to chiral compounds. Usually one of the stereoisomers has a stronger teratogenic effect than the other one (Nau et al., 1991, Pharmacol. Toxicol. 69, 310-321) and the more teratogenic isomer more efficiently activates PPAR δ (Lampen et al, 1999). Therefore, this isomer can be expected to inhibit HDACs more strongly (this invention). Thus, different rules apply to the selection of substituents in the R¹ and R² position. The present invention encompasses the racemic mixtures of the respective compounds, the less active isomers, and in

particular the more active isomers.

[0019] The hydrocarbon chains R^1 and R^2 may comprise one or several heteroatoms (e.g. O, N, S) replacing carbon atoms in the hydrocarbon chain. This is due to the fact that structures very similar to that of carbon groups may be adopted by heteroatom groups when the heteroatoms have the same type of hybridization as a corresponding carbon group.

[0020] R^1 and R^2 may be substituted. Possible substituents include hydroxyl, amino, carboxylic and alkoxy groups as well as aryl and heterocyclic groups.

[0021] Preferably, R^1 and R^2 independently comprise 2 to 10 carbon atoms. It is also preferred that R^1 and R^2 independently are saturated or comprise one double bond or one triple bond. In particular, one of the side chains (R^1) may preferably contain sp^1 hybridized carbon atoms in position 2 and 3 or heteroatoms which generate a similar structure. This side chain should comprise 3 carbon or heteroatoms but longer chains may also generate HDAC-inhibiting molecules. Also inclusion of aromatic rings or heteroatoms in R^2 is considered to generate compounds with HDAC inhibitory activity because the catalytic site of the HDAC protein apparently accommodates a wide variety of binding molecules. With the novel observation that teratogenic VPA derivatives are HDAC inhibitors, also compounds which have previously been disregarded as suitable antiepileptic agents are considered as HDAC inhibitors under this invention. In particular, but not exclusively, compounds having a propinyl residue as R^1 and residues of 7 or more carbons as R^2 , are considered (Lampen et al, 1999).

[0022] Preferably, the group " COR^3 " is a carboxylic group. Also derivatization of the carboxylic group has to be considered for generating compounds with potential HDAC inhibitory activity. Such derivatives may be halides (e.g. chlorides), esters or amides. When R^3 is alkoxy, the alkoxy group comprises 1 to 25, preferably 1-10 carbon atoms. When R^3 is a mono- or dialkylated amino group, the alkyl substituents comprise 1 to 25, preferably 1-10 carbon atoms. An unsubstituted amino group, however, is preferred.

[0023] According to the present invention also pharmaceutically acceptable salts of a compound of formula I can be used.

[0024] The compounds which are most preferably used according to the present invention are VPA, S-4-yn VPA, EHXA (Ethyl hexanoic acid).

[0025] The compounds are useful for inhibiting mammalian (to cover cell lines for use in in vitro assays) and in particular human histone deacetylases HDAC 1-3 (class I) and HDAC 4-7 (class II).

[0026] The compounds may be used to induce the differentiation of cells such as undifferentiated tumour cells. Presumably, this reflects a general mechanism, as differentiation can be induced in F9 teratocarcinoma cells, MT 450 breast cancer cells, HT-29 colon carcinoma cells and several leukemia cell lines.

Another aspect of the present invention is the use of a compound of formula I for the manufacture of a medicament for the treatment of a disease which is associated with gene-specific hypoacetylation of histones. There are a number of diseases which are associated with aberrant repression of specific genes which correlates with a local level of histone acetylation below the regular level. Examples of such diseases are leukemia, epithelial teratocarcinoma, estrogen receptor-independent breast cancer, non-Hodgkin lymphoma, adrenocortical adenoma and thyroid resistance syndrome. In a preferred embodiment the compounds are used for the manufacture of a medicament for the treatment of acute promyelocytic leukemia (APL), acute myelocytic leukemia (AML) or MDS (myelodysplasia syndrome).

[0027] The compounds and salts thereof can be formulated as pharmaceutical compositions (e.g. powders, granules, tablets, pills, capsules, injections, solutions, foams, enemas and the like) comprising at least one such compound alone or in admixture with pharmaceutically acceptable carriers, excipients and/or diluents. The pharmaceutical compositions can be formulated in accordance with a conventional method. Specific dose levels for any particular patient will be employed depending upon a variety of factors including the activity of specific compounds employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy. The active ingredient will preferably be administered in an appropriate amount, for example, selected from the range of about 10 mg/kg to 100 mg/kg body weight a day orally or intravenously. The dose levels are not specifically restricted as long as serum levels of 0.05 mM to 3 mM, preferably of about 0.4 mM to 1.2 mM are achieved.

[0028] Another aspect of the invention is a method for the identification of substances having histone deacetylase inhibitory activity which comprises providing a derivative of valproic acid, determining its histone deacetylase inhibitory activity, and selecting the substance if the substance has histone deacetylase inhibitory activity. Valproic acid can serve as a lead substance for the identification of other compounds exhibiting histone deacetylase inhibitory activity. Thereby compounds may be selected which show increased HDAC inhibitory activity at lower doses and serum levels and have decreased effects on the central nervous system such as sedating activity. Another parameter that may be optimised is the appearance of the hepatotoxic effect. Compounds may be selected which show a reduced liver toxicity. The derivatives may be provided by synthesising compounds which comprise additional and/or modified substituents. The HDAC inhibitory activity may be determined by a transcription repression assay, a Western Blot which detects acetylation of histone H3 and/or histone H4, or by an enzymatic assay.

- [0029]** The transcriptional assay for repressor activity exploits activation and derepression of a Gal4-dependent reporter gene. This assay can be performed either by transient transfection of mammalian cell lines (e.g. HeLa, 293T, CV-1) or with specifically constructed permanent cell lines. Transcription factors such as thyroid hormone receptor, PPAR δ , retinoic acid receptor, N-CoR and AML/ETO repress transcription when they bind to a promoter containing UAS elements as fusion proteins with the heterologous DNA-binding domain of the yeast Gal4 protein. In the absence of the Gal4-fusion protein the reporter gene has a high basal transcriptional activity due to the presence of binding sites for other transcription factors in the thymidine kinase promoter. The Gal4 fusion proteins repress this activity by up to 140-fold. HDAC inhibitors induce relief of this repression which can be detected as an increase in reporter gene activity (e.g. by luciferase assay).
- [0030]** Histone deacetylase inhibitors induce the accumulation of N-terminally hyperacetylated histones H3 and H4. These acetylated histones can be detected by Western blot analysis of whole cell extracts or of histone preparations from histone deacetylase inhibitor-treated cells using antibodies specific for the acetylated N-terminal lysine residues of histones H3 and H4.
- [0031]** The enzymatic assay for HDAC activity records the release of ^3H -labeled acetic acid from hyperacetylated substrates. Sources of HDAC activity can be co-immunoprecipitates with antibodies directed against N-CoR (or other repressors known to recruit HDACs) or crude cell extracts containing histone deacetylases (e.g. HeLa, 293T, F 9). Substrates may be either chemically ^3H -acetylated peptides corresponding to the N-termini of histones H3 or H4 or histone proteins isolated from metabolically labelled cells which were treated with HDAC inhibitors. After extraction with ethyl acetate the release of ^3H -labeled acetic acid is detected by liquid scintillation counting.
- [0032]** Another aspect of the invention is the use of VPA or derivatives thereof to define genes which are induced by said compounds in cells such as primary human or rodent cells, leukemic cells, other cancer cells or tumor cell lines. The invention therefore provides a method for the identification of genes induced by VPA or a derivative thereof which comprises providing two populations of cells which are substantially identical, contacting one of the populations with VPA or a derivative thereof, and detecting genes or gene products which are expressed in the population which had been contacted with VPA or a derivative thereof at a level significantly higher than in the population which had not been contacted with VPA or a derivative thereof. Methods to define such genes that are induced by VPA include established technologies for screening large arrays of cDNAs, expressed sequence tags or so-called unigene collections. Also the use of subtractive hybridization techniques is suitable to define genes which are induced by VPA or derivatives thereof. The use of these methods to identify potential targets for drug development downstream of HDAC-inhibition is part of this invention. Considering the low general toxicity of VPA in the organism compared to other HDAC-inhibitors it is a specific aspect of this invention to use VPA or derivatives thereof for defining target genes which are selectively regulated by either VPA or other HDAC inhibitors like trichostatin A.
- [0033]** The present invention provides novel possibilities to treat various cancer diseases. Applicant found that VPA and derivatives thereof are potent HDAC inhibitors. The HDAC inhibitors known so far are either nonspecific like butyrate, or toxic like TSA and TPX. VPA has the advantage that it is already an approved drug for the treatment of epilepsy. Thus, a vast amount of data concerning side effects and pharmaceutical acceptability are available.
- [0034]** Figure 1 describes the histone deacetylase inhibitor-like activation of PPAR δ by VPA (example 1).
- [0035]** Figure 2 shows that VPA activates several transcription factors in addition to PPAR δ (example 2).
- [0036]** Figure 3 shows VPA-induced accumulation of hyperacetylated histones H3 and H4 (example 3).
- [0037]** Figure 4 shows the biochemical analysis of histone deacetylase activity in the absence or presence of VPA (example 4).
- [0038]** Figure 5 shows indicators of VPA induced differentiation in HT-29 colonic carcinoma cells and F9-teratocarcinoma cells. The phenotypes of F9-teratocarcinoma cells differentiated by VPA or the histone deacetylase inhibitor trichostatin A appear identical (example 5).
- [0039]** The following examples further illustrate the invention.

Example 1

Activation of a PPAR δ -glucocorticoid receptor hybrid protein by VPA

- [0040]** A reporter gene cell line for activation of the PPAR δ ligand binding domain was constructed in CHO cells. A subclone of CHO cells was used which contained a transgenic reporter gene expressing a secreted form of the human placental alkaline phosphatase under control of the glucocorticoid receptor-dependent LTR-promoter of the mouse mammary tumor virus (Göttlicher et al. (1992) Proc. Natl. Acad. Sci. USA 89, pp. 4653-4657). A hybrid receptor comprising the amino-terminus of the glucocorticoid receptor fused to the ligand binding domain of PPAR δ was expressed in these cells essentially as described for the expression of the corresponding hybrid of PPAR α (Göttlicher et al., 1992, ibd.). The ligand binding domain of PPAR δ was used starting at amino acid 138 as deduced from the sequence published by Amri et al. (J. Biol. Chem. 270 (1995) pp. 2367-2371). Activation of the PPAR δ ligand binding domain in these

cells induces expression of the alkaline phosphatase reporter gene which is detectable by an enzymatic assay from the cell culture supernatant. Similar cells expressing the full length glucocorticoid receptor served as negative controls for specificity of receptor activation. For the experiment shown in figure 1 the PPAR δ hybrid receptor expressing cells were seeded at 20 % confluency into 24-well culture dishes and treated for 40 h with the PPAR δ ligand carbocyclic prostaglandin I₂ (PGI, 5 μ M), VPA (1 or 2 mM), or the histone deacetylase inhibitors sodium butyrate (B, 0,2-5 mM) and trichostatin A (TSA, 300 nM). Reporter gene activity was monitored by an enzymatic assay (alkaline phosphatase). Values except for butyrate are means \pm S.D. from triplicate determinations in 2 independent experiments which were normalized according to cPGI-induced activity (figure 1). The highly synergistic activation of the reporter gene by VPA together with the PPAR δ ligand cPGI (P+V) which is similar to the synergistic activation by Trichostatin A together with cPGI (P+T), and the lack of synergism with trichostatin (T+V) or butyrate (not shown) indicate that VPA does not act like a bona fide ligand to PPAR δ . VPA rather affects PPAR δ activity by a mechanism which lies in the same sequence of events by which also the inhibitors of corepressor-associated histone deacetylases induce transcriptional activity of PPAR δ .

Example 2

Activation of transcriptional repressors by VPA

[0041] The transcription factors thyroid hormone receptor (TR), peroxisome proliferator activated receptor δ (PPAR δ), retinoic acid receptor (RAR), the corepressor N-CoR and the AML/ETO fusion protein repress transcription when they bind to a promoter containing UAS sites (Gal4 response element) as fusion proteins with the heterologous DNA binding domain of the yeast Gal4 protein. In the absence of the Gal4 fusion protein a luciferase reporter gene is transcribed at a high basal level due to the presence of binding sites for other transcription factors in the thymidine kinase (TK) promoter. Hela cells were transfected with a UAS TK luciferase reporter plasmid (Heinzel et al., 1997, Nature 387, pp 43-48) and expression plasmids for the indicated Gal4 fusion proteins using the calcium phosphate precipitate method. After 24 h the medium was changed and cells were incubated with histone deacetylase inhibitors for a further 24 h. Transcriptional repression is measured as luciferase activity relative to the baseline of cells transfected with an expression plasmid for the Gal4 DNA binding domain alone (Figure 2). The Gal4 fusion proteins repress this baseline activity by up to 140 fold. VPA at a concentration of 1 mM (close to the serum levels which are reached during therapeutic use) induces relief of this repression which is indicated as an increase in reporter gene activity. A relief of repression is also found after treatment with established histone deacetylase inhibitors (10 nM Trapoxin, 100 nM TSA) as well as after partial activation of TR and PPAR δ by their respective ligands. A combination of ligand and HDAC inhibitors (including VPA) results in a synergistic effect, indicating that different molecular mechanisms are involved. Figure 2 shows that VPA affects the activity of several distinct transcription factors and cofactors. This finding suggests that VPA acts on a common factor in the regulation of gene expression such as corepressor-associated histone deacetylases rather than on individual transcription factors or receptors (e.g. as a ligand).

Example 3

Accumulation of hyperacetylated histones in VPA-treated cells

[0042] VPA and established histone deacetylase inhibitors like sodium butyrate (NaBu) or trichostatin A (TSA) induce the accumulation of hyperacetylated histones H3 and H4. These acetylated histones can be detected by Western blot analysis in cell extracts of appropriately treated cells. Figure 3 shows the results of such an analysis from a representative experiment. In this experiment both the time course of VPA-induced hyperacetylation (A) and the required VPA concentration (B) were determined.

(A) For the time course analysis F9 cells were seeded into 6-well culture dishes 30 h before the intended time point of analysis. Individual cultures were treated at the indicated time points before analysis by addition of 10-fold concentrated stock solutions in culture medium of VPA or trichostatin A. Whole cell extracts were prepared by rinsing the cell cultures twice in ice-cold phosphate buffered saline and lysis of cells in 250 μ l of sample buffer for denaturing SDS gel electrophoresis. DNA of collected samples was sheared by sonication and samples were separated on a 15% denaturing polyacrylamide gel. Acetylated histones H3 and histone H4 were detected by Western blot analysis using commercially available antibodies (Upstate Biotechnology) specific for the acetylated forms of histones (Ac-H3, Cat-Nr.: 06-599; Ac-H4, Cat-Nr.: 06-598). Equal loading of the lanes was confirmed by staining a part of the polyacrylamide gel by Coomassie blue.

(B) For determination of the required VPA dose F9 cells were cultured in 6-well culture dishes for 8 h prior to

addition of VPA at the indicated concentrations. Whole cell extracts were prepared 16 h after treatment as described above. Analysis for acetylated histones H3 and H4 was performed as described in (A). VPA concentrations in the range of blood serum levels reached during therapeutic use of VPA as antiepileptic agent in humans induce hyperacetylation of histones H3 and H4. At serum levels only slightly exceeding those intended for antiepileptic therapy VPA induces histone hyperacetylation as efficiently as sodium butyrate or trichostatin A used at concentrations which are expected to have a maximum effect. This experiment indicates that VPA or a metabolite formed in F9 cells inhibits histone deacetylase activity.

Example 4

VPA inhibits histone deacetylase activity *in vitro*

[0043] Immune precipitates from whole cell extracts using antibodies against the corepressor N-CoR or mSin3 contain histone deacetylase activity. This enzymatic activity is measured by incubating the immune precipitates with radioactively acetylated histone substrates from cells in which histones have been hyperacetylated in the presence of ^3H -acetate. The release of ^3H -acetate is detected as a measure of enzymatic activity by extraction with ethyl acetate and subsequent liquid scintillation counting (Figure 4). Addition of the histone deacetylase inhibitor trichostatin A (TSA, 10^{-7} M) to the reaction *in vitro* severely inhibits the enzymatic activity. VPA (0.2 mM, 1 mM, 5 mM) and the related compounds ethyl hexanoic acid (EHXA, 0.008 mM, 0.04 mM, 0.2 mM, 1 mM, 5 mM), R-4-yn VPA (0.2 mM, 1 mM, 5 mM) and S-4-yn VPA (0.2 mM, 1 mM, 5 mM) were tested for HDAC inhibitory activity. The assays were performed with N-CoR immunoprecipitates from 293T cells in duplicate. Immunoprecipitates were pretreated with HDAC inhibitors for 15 min prior to the addition of substrate and subsequent incubation for 2.5 h at 37°C (untreated enzyme activity 2,205 cpm = 100%). Precipitates of a preimmune serum served as a negative control. EC_{50} values are 0.6 mM for VPA, 0.2 mM for EHXA and 0.3 mM for S-4-yn VPA, whereas the stereoisomer R-4-yn VPA is inactive. These data show that VPA by itself rather than a cellular metabolite inhibits histone deacetylase activity.

Example 5

Induction of cell differentiation in F9 teratocarcinoma, MT-450 breast cancer cells and HT-29 colonic cancer cells

[0044] Histone deacetylase inhibitors and VPA in particular induce differentiation of dedifferentiated tumorigenic cells. Cell differentiation is associated with a decrease in cell proliferation, morphological alterations and the appearance of expression of markers of the differentiated phenotype. The reduction of proliferation rate was shown in three examples, e.g. F9 teratocarcinoma, estrogen independent MT-450 breast cancer and HT-29 colonic carcinoma cells. F9 and HT-29 cells were cultured for 36 h in the absence or the presence of 1 mM VPA in 96-well culture dishes. 37 kBq of ^3H -thymidine were added for additional 12 h of culture. MT-450 cells were cultured for 72 h prior to a 1 h ^3H -thymidine labelling period. Incorporation of ^3H -thymidine into DNA was determined by automatic cell harvesting and liquid scintillation counting. VPA pretreatment reduced the rate of thymidine incorporation by $48 \pm 5\%$, $63 \pm 8\%$, and $52 \pm 8\%$ in F9, MT-450, and HT-29 cells, respectively. The dose-response for the reduction of thymidine incorporation into HT-29 cells (Figure 5A) was determined by the same experimental procedure. The induction of a cell differentiation marker was shown in F9 teratocarcinoma cells (Figure 5B).


F9 teratocarcinoma cells were treated for 48 h with VPA (1 mM), sodium butyrate (B, 1 mM) and trichostatin A (TSA, 30 nM). Differentiation was followed by morphological criteria, a reduced rate in the increase of cell number (data not shown), the drop of ^3H -thymidine incorporation by 48% during a 12 h pulse labeling period (see above) and the appearance of nuclear AP-2 protein (Figure 5B) as a specific marker of histone deacetylase inhibitor-induced differentiation of F9 cells. Nuclear AP-2 protein was detected in nuclear extract which had been prepared by mild detergent lysis (25 mM Tris, pH 7.5; 1 mM EDTA, 0.05% NP40) of treated or non-treated F9 cells, recovery of nuclei by centrifugation (3000 x g, 5 min) and lysis of nuclei in sample buffer for denaturing SDS gel electrophoresis. Nuclear extracts were separated on a 9 % SDS polyacrylamide gel. AP-2 protein was detected by Western blot analysis using a rabbit polyclonal antibody (Santa Cruz, Cat.-No.: SC-184) at a dilution of 1/1000 in Tris buffered saline containing 3% non-fat dry milk and 0.05% Tween 20. Both VPA and trichostatin A induce nuclear AP-2 protein whereas the activity of butyrate at the chosen concentration is weak. Since appearance of AP-2 is a delayed effect which is only detectable after 36 to 40 h of VPA treatment the weak activity of butyrate may be caused by efficient metabolism of the compound. Nevertheless, VPA induces differentiation of the epithelial F9 cell line in a way indistinguishable from differentiation by other histone deacetylase inhibitors.

Claims

1. The use of a compound of formula I

5

10



I

15

wherein R¹ and R² independently are a linear or branched, saturated or unsaturated, aliphatic C₁₋₂₅ hydrocarbon chain which optionally comprises one or several heteroatoms and which may be substituted, R³ is hydroxyl, halogen, alkoxy or an optionally alkylated amino group, or of pharmaceutically acceptable salts thereof as an inhibitor of an enzyme having histone deacetylase activity.

20

2. A use according to claim 1, wherein R¹ and R² independently are a linear or branched C₂₋₁₀ hydrocarbon chain which chain optionally comprises one double or triple bond.

3. A use according to claim 1 or 2, wherein the compound is selected from the group consisting of VPA, S-4-yn VPA and EHXA (Ethyl hexanoic acid).

25

4. A use according to anyone of claims 1 to 3, wherein the compound is valproic acid.

5. A use according to anyone of claims 1 to 4, wherein the enzyme having histone deacetylase activity is a mammalian, preferably a human histone deacetylase.

30

6. A use according to claim 5, wherein the human histone deacetylase is selected from the group consisting of HDACs 1-7.

7. A use according to anyone of claims 1 to 6, wherein the compound is used for the induction of differentiation of cells.

35

8. The use of a compound as defined in claims 1 to 4 for the manufacture of a medicament for the treatment of a disease which is associated with local gene-specific hypoacetylation of histones.

40

9. A use according to claim 8, wherein the disease is selected from the group consisting of leukemia, epithelial teratocarcinoma, estrogen receptor-independent breast cancer, non-Hodgkin lymphoma, adrenocortical adenoma, colon cancer, and thyroid resistance syndrome.

10. A use according to claim 9, wherein the disease is selected from the group consisting of acute promyelocytic leukemia (APL), acute myelocytic leukemia (AML), and myelodysplasia syndrome (MDS).

45

11. A method for the identification of substances having histone deacetylase inhibitory activity which comprises

providing a derivative of valproic acid;

determining the histone deacetylase inhibitory activity of the derivative;

50

selecting the substance if the substance has histone deacetylase inhibitory activity.

12. A method according to claim 11, wherein the method comprises the steps of

55

determining the sedating effect of the substance and

selecting the substance if the substance has histone deacetylase inhibitory activity and a lower sedating effect than valproic acid.

13. A method according to claim 11 or 12, wherein the histone deacetylase inhibitory activity is determined by
a transcription repression assay,

5 a Western Blot detecting acetylation of histone H3 or histone H4,

or by enzymatic deacetylase assay.

14. A method for the identification of genes induced by valproic acid or a derivative thereof which comprises

10

providing two populations of cells which are substantially identical;

contacting one of the populations with VPA or a derivative thereof;

15

detecting genes or gene products which are expressed in the population which had been contacted with VPA
or a derivative thereof at a level significantly higher than in the population which had not been contacted with
VPA or a derivative thereof.

20

15. A method according to claim 14, wherein subtractive hybridization or screening of arrays of cDNA samples, ex-
pressed sequence tags or unigene collections is employed.

25

30

35

40

45

50

55

Figure 1




Figure 2

Relief of Repression by HDAC-Inhibitors




Figure 3




Figure 4




Figure 5A





Figure 5B





European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 11 4088

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 98 29114 A (BEACON LABORATORIES) 9 July 1998 (1998-07-09) * page 6, line 16 - line 35 * * page 7, line 1 - line 25 * * page 12, line 19 - line 22 * * page 31; table 1 * * page 32 - page 38 *	1,7-10	A61K31/19 A61P43/00 A61P35/00 A61P35/02 A61P5/02 C12Q1/66 C12Q1/34 G01N33/68 C12Q1/68
X	WO 97 47307 A (THE UAB RESEARCH FOUNDATION) 18 December 1997 (1997-12-18) * page 2, line 1 - line 3 * * page 8, line 9 - line 20 * * claims 2-5 *	1	
Y	---	13	
Y	WO 99 23885 A (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 20 May 1999 (1999-05-20) * the whole document, especially page 9 lines 14-28, page 10, pages 30-34 and claims 28-48 *	1,2,13	
A	---	3-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	WO 98 48825 A (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 5 November 1998 (1998-11-05) * the whole document *	13	A61K C12Q
A	---	1-12	
	---	-/--	
-The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
THE HAGUE		12 September 2001	GAC, G
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document	

EPO FORM 1503 03 87 (P04CC1)



European Patent
Office

Application Number
EP 00 11 4088

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☒ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

1-13 searched incompletely



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 11 4088

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	WO 97 35990 A (PRESIDENT AND FELLOWS OF HARVARD COLLEGE) 2 October 1997 (1997-10-02) * page 48, line 15 - line 45 * * page 49 * * page 52, line 1 - line 3 * * page 53, line 25 - line 35 * * page 54 * * page 59, line 27 - line 65 * * page 82 - page 84 * * page 97 - page 105 * * example 3 *	13	
Y	WO 97 11366 A (MERCK & CO. INC.) 27 March 1997 (1997-03-27) * page 31 *	13	
Y	US 5 858 365 A (D.V. FALLER) 12 January 1999 (1999-01-12) * column 11 - column 15 *	1,2	
A		3,4,9,10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A,D	WO 99 37150 A (SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH) 29 July 1999 (1999-07-29) * the whole document *	1-10	
-/--			
-The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 12 September 2001	Examiner GAC, G
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1523 03 82 (P24,001)



European Patent
Office

**LACK OF UNITY OF INVENTION
SHEET B**

Application Number
EP 00 11 4088

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-13

Use of a compound of claim 3 as a histone deacetylase (HDA) inhibitor to treat diseases of claims 9 and 10, and methods for the identification of substances having HDA inhibitory activity using valproic acid.

2. Claims: 14-15

Method of identifying genes induced by valproic acid using two populations of cells and measuring gene expression therein, as far as not already covered by previous subject.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 11 4088

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	YOSHIDA M ET AL: "POTENT AND SPECIFIC INHIBITION OF MAMMALIAN HISTONE DEACETYLASE BOTH IN VIVO AND IN VITRO BY TRICHOSTATIN A" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 265, no. 28, 5 October 1990 (1990-10-05), pages 17174-17179, XP000616087 ISSN: 0021-9258 * the whole document *	1,11,13	
A,D	US 5 672 746 A (NAU ET AL.) 30 September 1997 (1997-09-30) * the whole document *	1-3,9	
A	DATABASE MEDLINE [Online] AN=94307302, XP002164292 * abstract * & BRICHARD ET AL.: "Haematological disturbances during long-term valproate therapy" EUROPEAN JOURNAL OF PEDIATRICS, vol. 153, no. 5, May 1994 (1994-05), pages 378-380, * abstract *	10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
-/--			
-The present search report has been drawn up for all claims			
Place of search:		Date of completion of the search:	
THE HAGUE		12 September 2001	
		Examiner	
		GAC, G	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03 82 (P24C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 11 4088

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	LETIZIA C ET AL: "REDUCTION OF AN ACTH SECRETING ADENOMA IN A PATIENT WITH NELSON'S SYNDROME CHRONICALLY TREATED WITH SODIUM VALPROATE" EUROPEAN JOURNAL OF INTERNAL MEDICINE, ELSEVIER, AMSTERDAM, NL, vol. 5, no. 4, October 1994 (1994-10), pages 325-328, XP000997468 ISSN: 0953-6205 * the whole document *	9	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	DATABASE MEDLINE [Online] STN AN = 79170906, XP002166105 * abstract * & MORI ET AL.: "Effect of alpha-mercaptopropionylglycine (alpha-MPG) and sodium dipropylacetate (DPA) on antibody formation. IV. Tumor immunity" FOLIA PHARMACOL. JAPONICA, vol. 74, no. 8, November 1978 (1978-11), pages 907-923,	9	
A	TITTLE T V ET AL: "EFFECT OF ANTIPILEPTIC DRUGS ON GROWTH OF MURINE LYMPHOID TUMOR CELLS IN SINGLE-CELL CULTURE" EPILEPSIA, RAVEN PRESS LTD., NEW YORK, US, vol. 33, no. 4, July 1992 (1992-07), pages 729-735, XP000997403 ISSN: 0013-9580 * the whole document *	9,10	
-/--			
-The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 12 September 2001	Examiner GAC, G
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons * : member of the same patent family, corresponding document	

EPO FORM 1503 (01.92) (P04.001)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 11 4088

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	FISCHKOFF ET AL.: "Induction of neutrophilic differentiation of human promyelocytic leukemic cells by branched-chain carboxylic acid anticonvulsant drugs" J. BIOL. RESPONSE MODIFIERS, vol. 3, no. 2, 1984, pages 132-137, XP000997488 * the whole document *	9,10	
Y	WD 96 06821 A (AMERICAN BIOGENIC SCIENCES) 7 March 1996 (1996-03-07) * the whole document, especially page 12 lines 14-15, page 13, page 14 lines 4-12, page 17 lines 10-14, page 20 lines 1-8 and claims 9,30-35 *	9,10	
A	---	3,4,7	
A	GÖTTLICHER ET AL.: "Cellular actions of valproic acid and its teratogenic derivatives: activation of peroxisome proliferator activated receptors (PPARs) and differentiation of teratocarcinoma cells" NAUNYN-SCHMIEDBERG ARCH. PHARMACOL., vol. 358, no. 4 suppl.3, October 1998 (1998-10), page r775 XP002166104 * abstract 43 *	9,12	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	12 September 2001	GAC, G	
CATEGORY OF CITED DOCUMENTS		I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 11 4088

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	<p>DATABASE MEDLINE [Online] stn an = 1998351137 (medline an DN= 98351137), XP002166106 * abstract and indexing (CT field) * & CHYBICKA ET AL.: "Treatment outcome for myelodysplastic syndromes (MDS) obtained by the polish Children's Leukemia/Lymphoma Study Group" KLINIKA HEMATOLOGII I CHOROZ ROZROSTOWYCH DZIECI AM WE WROCLAWIU, vol. 99, no. 2, February 1999 (1999-02), pages 155-158,</p>	10	
A	<p>SKLADCHIKOVA ET AL.: "Valproic acid, but not its non-teratogenic analogue 2-isopropylpentanoic acid, affects proliferation, viability and neuronal differentiation of the human teratocarcinoma cell line NTera-2" NEUROTOXICOLOGY, vol. 19, no. 3, June 1998 (1998-06), pages 357-370, XP000997593 * the whole document *</p>	9	<p>TECHNICAL FIELDS SEARCHED (Int.Cl.7)</p>
<p>-The present search report has been drawn up for all claims</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		12 September 2001	GAC, G
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 01/02 (P04001)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 11 4088

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12-09-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9829114 A	09-07-1998	US 6130248 A	10-10-2000
		AU 5617398 A	31-07-1998
		EP 0961614 A	08-12-1999
WO 9747307 A	18-12-1997	AU 3391097 A	07-01-1998
WO 9923885 A	20-05-1999	AU 1395999 A	31-05-1999
		EP 1037533 A	27-09-2000
WO 9848825 A	05-11-1998	AU 7263198 A	24-11-1998
		EP 1017410 A	12-07-2000
WO 9735990 A	02-10-1997	AU 2990597 A	17-10-1997
WO 9711366 A	27-03-1997	AU 712801 B	18-11-1999
		AU 6979096 A	09-04-1997
		CA 2231251 A	27-03-1997
		EP 0855024 A	29-07-1998
		JP 11514857 T	21-12-1999
		US 6110697 A	29-08-2000
		US 5922837 A	13-07-1999
US 5858365 A	12-01-1999	AU 696167 B	03-09-1998
		AU 7976794 A	22-05-1995
		EP 0731712 A	18-09-1996
		JP 9507050 T	15-07-1997
		RO 115498 B	30-03-2000
		WO 9511699 A	04-05-1995
WO 9937150 A	29-07-1999	US 6262116 B	17-07-2001
US 5672746 A	30-09-1997	AT 200890 T	15-05-2001
		AU 3415195 A	22-03-1996
		DE 19502050 A	14-03-1996
		DE 69520832 D	07-06-2001
		DE 69520832 T	09-08-2001
		DK 778820 T	20-08-2001
		EP 0778820 A	18-06-1997
		JP 10505064 T	19-05-1998
		NZ 292388 A	29-03-1999
		US 6274624 B	14-08-2001
		WO 9606821 A	07-03-1996
		US 5672746 A	30-09-1997
		AT 200890 T	15-05-2001
		AU 3415195 A	22-03-1996
WO 9606821 A	07-03-1996	US 5672746 A	30-09-1997
		AT 200890 T	15-05-2001
		AU 3415195 A	22-03-1996

EPO FORM P459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

